TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Documented cancer of the pancreas who have failed (or are not candidates for) standard therapy~2. ECOG Performance Status of 0 to 1~3. Adequate organ function as defined by study-specified laboratory tests~4. Must use acceptable form of birth control through the study and for 28 days after final dose of study drug~5. Signed informed consent form~6. Willing and able to comply with study procedures~Exclusion Criteria:~1. Currently have or have history of certain study-specified heart, liver, kidney, lung, neurological, immune or other medical conditions~2. Clinical metabolic or laboratory abnormalities defined as Grade 3 or 4 of the National Cancer Institute's (NCI's) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0~3. Systemically active steroids~4. Another investigational product within 28 days prior to receiving study drug~5. Major surgery or significant traumatic injury (or unhealed surgical wounds) occurring within 28 days prior to receiving study drug~6. Infection with HIV, hepatitis B or C at screening~7. Pregnant or lactating~8. Conditions, including alcohol or drug dependence, or intercurrent illness that would affect the patient's ability to comply with study visits and procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: Ipilimumab Alone (Type: EXPERIMENTAL): Ipilimumab alone
- Arm 2: Ipilimumab + Pancreatic Cancer Vaccine (Type: EXPERIMENTAL): Ipilimumab + Pancreatic Cancer Vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adolescents and preadolescents with no prior sexual history~Exclusion Criteria:~* Subjects with compromised immune system or have a history of severe allergic reaction

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 15 Years
- Healthy Volunteers: t

Study Arms:
- qHPV Vaccine in Base Study (Type: EXPERIMENTAL): Represents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 6.
- Placebo in Base Study (Type: PLACEBO_COMPARATOR): Represents participants who were randomized into the Placebo Group, who received three 0.5 mL intramuscular injections of placebo at Day 1, Month 2, and Month 6.
- qHPV Vaccine in Extension Study (Type: EXPERIMENTAL): Represents participants originally enrolled into the Placebo Group who continued in the study to receive 0.5 mL intramuscular injections of V501 (qHPV) at Month 30, Month 32, and Month 36.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Interest of Hypnosis on Pain Management During a Guided Echo Infiltration of the Hand

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with an indication of a first hand infiltration under ultrasound examination~* Major patient~* Patient with capacity to understand the protocol and has given oral consent to participate in the research,~* Patient with social security coverage.~Exclusion Criteria:~* Patient having preventively applied a pain patch to the area to be infiltrated~* Contraindication to infiltrations ( imbalanced diabetes, imbalanced,hypertension, ongoing infections).~* Hearing impaired patient~* Patient under guardianship/curtel~* Minor~* Pregnant woman~* Patient participating in another intervention research protocol~* Patient unable to follow the protocol as judged by the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Infiltration (Type: ACTIVE_COMPARATOR): Ultrasound-guided hand infiltration
- Hypnosis (Type: EXPERIMENTAL): Hypnosis before Ultrasound-guided hand infiltration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Study of Patients With Thrombocytopenia Following HSCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Platelet count ≤ 30 × 109/L persistently at day 60 post-HSCT or later;~2. Neutrophil and hemoglobin were well recovered;~3. Full donor chimerism was achieved;~4. No response to conventional treatments (e.g. thrombopoietin, immunoglobulin, glucocorticoid alone or in combination) for a duration of at least 4 weeks;~Exclusion Criteria:~1. Patients with malignancy relapse;~2. Active infections;~3. Grade Ⅲ-Ⅳ acute GVHD or severe chronic GVHD according to National Institute of Health criteria;~4. Severe organ damage;~5. Thrombosis requiring treatment;~6. Received decitabine following the current transplantation.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental Group 1 (Type: EXPERIMENTAL): Decitabine in combination with rhTPO.
- Experimental Group 2 (Type: EXPERIMENTAL): Decitabine
- Control Group (Type: ACTIVE_COMPARATOR): Conventional treatment except decitabine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Docohexanoic Acid in Hemodialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age over 18 years~* chronic stabilized HD treatment for at least 3 months with functional vascular access (arteriovenous fistula or permanent catheter)~* equilibrated Kt/V urea (eKt/V)higher than 1.2~* informed consent form signed~Exclusion Criteria:~* exposure to corticosteroids and anti-inflammatory drugs or hospital admissions in last 3 months~* were with ongoing active illnesses, wasting, connective tissue disease, metastatic cancer or malignancy, HIV, uncontrolled chronic hepatic disease or transplantation prior to the start of the study.~* Patients with known hypersensitivity to any of fish intolerance or allergy, history of gastrointestinal bleeding, patients already receiving chronic anticoagulation therapy (antiplatelet agents or warfarin), and patients with terminal or life-threatening disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): The patients on this arm received usual medical care
- DHA supplementation (Type: ACTIVE_COMPARATOR): The patients on this arm received DHA supplementation (650 mg DHA/3 times/wk/post-HD session)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mojito Study (Mashed Or Just Integral Pill of TicagrelOr ? )

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients presenting within 12 hours from the onset of symptoms with STEMI~* Informed, written consent~Exclusion Criteria:~* Age \< 18 years or Age \> 75 years~* Active bleeding; bleeding diathesis; coagulopathy~* Increased risk of bradycardiac events~* History of gastrointestinal or genitourinary bleeding \<2 months~* Major surgery in the last 6 weeks~* History of intracranial bleeding or structural abnormalities~* Suspected aortic dissection~* Any other condition that may put the patient at risk or influence study results or investigator's opinion (severe hemodynamic instability, known malignancies or other comorbid conditions with life expectancy \<1 year)~* Administration in the week before the index event of clopidogrel, ticlopidine, prasugrel, ticagrelor, thrombolytics, bivalirudin, low-molecular weight heparin or fondaparinux .~* Concomitant oral or IV therapy with strong CYP3A inhibitors or strong CYP3A inducers, CYP3A with narrow therapeutic windows~* Known relevant hematological deviations: Hb \<10 g/dl, Thrombi. \<100x10\^9/l~* Use of coumadin derivatives within the last 7 days~* Chronic therapy with ticagrelor, prasugrel, clopidogrel or ticlopidine~* Known severe liver disease, severe renal failure~* Known allergy to the study medications~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ticagrelor mashed pills (Type: EXPERIMENTAL): Ticagrelor loading dose (LD) 180 mg as mashed pills
- Ticagrelor integral pills (Type: ACTIVE_COMPARATOR): Ticagrelor loading dose (LD) 180 mg as integral pills

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Homeopathic Treatment for Depression in Peri- and Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Major depression according to DSM-IV~* Moderate to severe depression according to 17-item Hamilton Rating Scale for Depression (14-24 score)~* No current use of homeopathic treatment for depression or antidepressants or anxiolytic drugs 3 months prior to study entry~* Not be currently taking psychotherapy for at least 3 months before study entry~* Early transition to menopause defined by a change in cycle length of 7 days or longer in either direction from the participant´s own baseline for at least 2 cycles~* Late transition to menopause defined as 3 to 11 months of amenorrhea~* Postmenopausal stage defined by 12 months or more of amenorrhea~* Capability and willingness to give informed consent and to comply with the study procedures~Exclusion Criteria:~* Pregnancy or breastfeeding~* Other psychiatric disorders different from moderate to severe depression (severe depression, schizophrenia, psychotic disorders, bipolar affective disorders, suicide attempt)~* Alcohol or other substance abuse~* Known allergy to fluoxetine~* Cancer or hepatic diseases

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Individualized homeopathic treatment (Type: EXPERIMENTAL): Selection of the individualized homeopathic remedy based on Hahnemann´s methodology after the case history of each patient.
- Fluoxetine (Type: EXPERIMENTAL): Selective serotonin reuptake inhibitor.
- Placebo (Type: PLACEBO_COMPARATOR): Fluoxetine placebo plus individualized homeopathic placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Growth Factor/Insulin-like Growth Factor (GH/IGF)-1 Axis in Obese Subjects in Treatment With Orlistat

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* women~* post-menopausal age~* class I-II obesity~* normal thyroid, liver, and kidney function~Exclusion Criteria:~* type 2 diabetes mellitus~* use of hypolipaemic agents

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- orlistat plus normo-caloric diet (Type: None): 10 subjects received normo-caloric diet plus + orlistat (Xenical, Roche, UK) at a dose of 120 mg tid. The duration of follow-up was 10 days
- normo-caloric diet (Type: None): 10 subjects received normo-caloric diet without the additional treatment. The duration of follow-up was 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of COPD (chronic obstructive pulmonary disease).~* Current or previous cigarette smokers with a smoking history of at least 10 pack-years.~* History of a least 1 COPD exacerbation in the 12 months prior to screening.~* Forced expiratory volume in one second (FEV1) of less than or equal to 50% of predicted normal.~Exclusion Criteria:~* Current diagnosis of asthma.~* Additional respiratory disorders other than COPD (eg, sarcoidosis, alpha-1 antitrypsin deficiency, cystic fibrosis, or active tuberculosis).~* Concurrent use of long-acting beta-agonists, long-acting anticholinergics, inhaled and oral corticosteroids, theophylline, investigational medications, ritonavir, and anti-leukotrienes.~* Lung resection surgery within 1 year of screening.~* Abnormal and clinically significant ECG findings at screening.~* Other inclusion and exclusion criteria will be evaluated at the first study visit.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chalazion Conservative Treatment Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* Patients age 18 and above~* Patient with a palpable chalazion on any eyelid~* Patients with multiple chalazia but only a single one on each lid~* Normal lid anatomy enabling lid eversion~Exclusion Criteria~* Patients with chalazia with atypical features (recurring chalazion, abnormal surrounding lid tissue, associated loss of lashes) that may indicate suspicion of malignancy~* Patients allergic to any agents being used in the study (tobramycin, dexamethasone)~* Patients who have had previous eyelid surgery to the same eyelid as the chalazion~* Patients under 18 years of age~* Patients without palpable lid chalazion~* Patients with multiple chalazia on one eyelid~* Patients with concurrent eyelid infection (cellulitis or conjunctivitis)~* Patients unable to give consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hot Compress (Type: ACTIVE_COMPARATOR): Hot Compress
- Tobrex (Type: ACTIVE_COMPARATOR): Hot Compress, Tobrex Drops, Tobrex Ointment
- Tobradex (Type: ACTIVE_COMPARATOR): Hot Compress, Tobradex Drops, Tobradex Ointment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients \>=18 years of age;~* chronic renal anemia;~* on dialysis therapy for at least 12 weeks before screening;~* receiving sc epoetin for at least 8 weeks before screening.~Exclusion Criteria:~* women who are pregnant, breastfeeding or using unreliable birth control methods;~* administration of another investigational drug within 4 weeks before screening, or during the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RO0503821 (1x/2 Weeks) (Type: EXPERIMENTAL): Eligible participants received RO0503821 (Mircera \[methoxy polyethylene glycol-epoetin beta\]) subcutaneously, once every two weeks for 52 weeks. Participants received a starting dose of RO0503821 60, 100, or 180 microgram (mcg) which was based on the epoetin dose of\<8000, 8000-16000, or \>16000 international units (IU)/week, administered during the week preceding the switch to the study drug.
- RO0503821 (1x/4 Weeks) (Type: EXPERIMENTAL): Eligible participants received RO0503821 subcutaneously, once every four weeks for 52 weeks. Participants received a starting dose of RO0503821 120, 200, or 360 mcg which was based on the epoetin dose of\<8000, 8000-16000, or \>16000 IU/week administered during the week preceding the switch to the study drug.
- Epoetin Reference (Type: ACTIVE_COMPARATOR): Eligible participants received their ongoing weekly subcutaneous dose of epoetin alfa or beta one, two or three times weekly for 52 weeks .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Treatment with diet and exercise alone or a stable dose of metformin, or sulfonylurea, or metformin plus a sulfonylurea for at least 3 months.~* Has HbA1c 6.0% to 11.0%, inclusive, at screening.~* Has a body weight of \>= 50 kg at screening.~Exclusion Criteria:~* Received any investigational drug or has participated in any type of clinical trial within 3 months prior to screening.~* Currently participates in any other interventional study.~* Is currently treated with any of the following excluded medications:~  * Sulfonylurea chlorpropamide~ * Thiazolidinedione within 3 months of screening.~ * Αlpha glucosidase inhibitor within 3 months of screening.~ * Meglitinide within 3 months of screening.~ * Insulin within 3 months of screening.~ * Pramlintide within 3 months of screening.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Sequence 1 (Type: EXPERIMENTAL): Exenatide 2.5 mcg - Exenatide 5 mcg - Placebo 0.02 mL
- Sequence 2 (Type: EXPERIMENTAL): Exenatide 2.5 mcg - Placebo 0.02 mL - Exenatide 5 mcg
- Sequence 3 (Type: EXPERIMENTAL): Placebo 0.02 mL - Exenatide 2.5 mcg - Exenatide 5 mcg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Newly diagnosed acute lymphoblastic leukemia or acute mixed lineage leukemia~  * Positive for Bcr-Abl fusion transcript (Philadelphia chromosome-positive disease) by RT-PCR~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Total bilirubin \< 2 mg/dL~* SGOT \< 3 times upper limit of normal (ULN)~* Alkaline phosphatase ≤ 2.5 times ULN (unless considered tumor-related)~* Creatinine \< 2.0 mg/dL ULN~* Serum amylase and lipase ≤ 1.5 times ULN~* Potassium, magnesium, and phosphorus normal (supplementation allowed)~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No rare hereditary problems with galactose intolerance, severe lactase deficiency, or glucose-galactose malabsorption~* No known sensitivity to any of the study drugs~* No severe medical condition that, in the opinion of the investigator, would preclude study participation~* No impaired cardiac function, including any of the following:~  * LVEF \< 45% or below the lower limit of normal by ECHO~ * Long QT syndrome or known family history of long QT syndrome~ * Clinically significant resting bradycardia (\< 50 beats per minute)~ * QTc \> 450 msec on baseline ECG (using the QTcF formula)~ * Myocardial infarction within the past 12 months~ * Other clinically significant heart disease, including any of the following:~    * Unstable angina~   * Congestive heart failure~   * Uncontrolled hypertension~   * Uncontrolled arrhythmias~* No other primary malignant disease requiring systemic treatment~* No acute or chronic liver, pancreatic, or severe renal disease~* No other severe and/or life-threatening medical disease~* No history of significant congenital or acquired bleeding disorder unrelated to cancer~* No impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug~* No history of non-compliance~PRIOR CONCURRENT THERAPY:~* More than 30 days since prior investigational agents~* No concurrent medications that have the potential to prolong the QTc interval~* No concurrent strong CYP3A4 inhibitors~* No concurrent therapeutic coumarin derivatives

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nilotinib+mVPD (Type: EXPERIMENTAL): Patients who were Philadelphia-positive, newly-diagnosed adult ALL and treated with nilotinib + mVPD treatment plan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete